Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models-Reference-Cited by-同舟云学术

Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models

Published:2021-01-03 Issue:3 Volume:39 Page:697-704
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Shiravi Fariba,Mohammadi Mehdi,Golsaz-Shirazi Forough,Bahadori Tannaz,Judaki Mohammad Ali,Fatemi Forough,Zare Hengameh Ahmadi,Haghighat Farzaneh Notash,Mobini Maryam,Jeddi-Tehrani Mahmood,Amiri Mohammad Mehdi,Shokri Fazel

Funder

Tehran University of Medical Sciences and Health Services

National Animal Modeling Network and In vivo Research, Council for Development of Stem Cell Sciences and Technologies, Vice-Presidency for Science and Technology

Avicenna Research Institute

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-020-01048-4.pdf

Reference40 articles.

1. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13):3159–3167

2. Roskoski R Jr (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74

3. Brandt-Rauf PW, Pincus MR, Carney WP (1994) The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog 5(2–3):313–329

4. Hubbard SR, Till JH (2000) Protein tyrosine kinase structure and function. Annu Rev Biochem 69(1):373–398